UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 1088-16
Program Prior Authorization-Notification
Medication Cequa™ (cyclosporine 0.09% ophthalmic solution)*, Miebo™
(perfluorohexyloctane), Restasis® (cyclosporine 0.05% ophthalmic
emulsion), Restasis MultiDose™ (cyclosporine 0.05% ophthalmic
emulsion)*, Tyrvaya™ (varenicline nasal spray), Vevye™
(cyclosporine 0.1%)*, Xiidra® (lifitegrast 5% ophthalmic solution)
P&T Approval Date 3/2006, 3/2007, 8/2008, 8/2009, 9/2010, 3/2011, 2/2012, 2/2013,
4/2014, 4/2015, 3/2016, 12/2016, 9/2017, 9/2018, 3/2019, 4/2020,
4/2021, 12/2021, 12/2022, 9/2023, 3/2024, 7/2024
Effective Date 8/18/2024
1. Background:
Cequa (cyclosporine 0.09% ophthalmic solution)*, Restasis (cyclosporine 0.05% ophthalmic
emulsion) and Restasis MultiDose (cyclosporine 0.05% ophthalmic emulsion)*, are indicated to
increase tear production in patients whose tear production is presumed to be suppressed due to
ocular inflammation associated with keratoconjunctivitis sicca.
Miebo (perfluorohexyloctane), Tyrvaya (varenicline nasal spray), Vevye (cyclosporine 0.1%)*
and Xiidra (lifitegrast 5% ophthalmic solution) are indicated for the treatment of the signs and
symptoms of dry eye disease.
2. Coverage Criteriaa:
A. Initial Authorization
1. Cequa*, Miebo, Restasis, Restasis MultiDose*, Tyrvaya, Vevye* or Xiidra will be
approved based on the following criterion:
a. Diagnosis of one of the following:
1) Moderate to severe keratoconjunctivitis sicca
2) Dry Eye Disease
-AND-
b. Medication will not be used in combination with another prescription product
for dry eye disease or keratoconjunctivitis sicca
Authorization will be issued for 12 months.
B. Reauthorization
1. Cequa*, Miebo, Restasis, Restasis MultiDose*, Tyrvaya, Vevye* or Xiidra will be
approved based on the following criterion:
a. Patient has demonstrated clinically significant improvement with therapy
© 2024 UnitedHealthcare Services, Inc.
-AND-
b. Medication will not be used in combination with another prescription product for
dry eye disease or keratoconjuctivitis sicca
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Cequa, Restasis MultiDose and Vevyeare typically excluded from coverage.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• Prior Authorization – Medical Necessity may be in place.
4. References:
1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc; December 2022
2. Miebo [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; May 2023.
3. Restasis [package insert]. Irvine CA: Allergan, Inc.: July 2017.
4. Restasis MultiDose [package insert]. Irvine, CA: Allergan, Inc.; October 2016.
5. Tyrvaya [package insert]. Princeton NJ: Oyster Point Pharma, Inc; February 2024.
6. Vevye [package insert]. Nashville, TN: Harrow Eye, LLC; November 2023.
7. Xiidra [package insert]. Bridgewater, NJ: Bausch & Lomb Americas Inc; December 2023.
6. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern 2023.
Program Notification – Dry Eye Disease
Change Control
4/2014 No changes to criteria. Updated references.
4/2015 Updating authorization criteria to 6 months and reauthorization criteria
to 12 months to align with prior authorization-medical necessity criteria
3/2016 Removed the Prior Authorization-Medical Necessity program language.
12/2016 Updated criteria to allow for Dry Eye Disease. Added Xiidra to criteria.
Changed name of criteria to Dry Eye Disease.
9/2017 Annual review. Administrative updates. Added Restasis MultiDose.
Updated references.
9/2018 Annual review. Administrative updates and updated references.
12/2018 Administrative change to add statement regarding use of automated
processes.
3/2019 Added Cequa and updated references.
4/2020 Annual review. Removed extemporaneously compounded cyclosporine
criteria. Updated references.
4/2021 Annual review. Updated references.
12/2021 Added Tyrvaya.
© 2024 UnitedHealthcare Services, Inc.
12/2022 Annual review. Added state mandate language. Updated references.
9/2023 Added Miebo and Vevye. Updated references.
3/2024 Updated initial authorization to 12 months. Updated references.
7/2024 Added concomitant therapy language. Updated references.
© 2024 UnitedHealthcare Services, Inc.